The Federal Trade Commission has approved Boston Scientific’s US$4 billion acquisition of British medtech company BTG, according to a regulatory filing.
Other antitrust authorities, such as the Federal Competition Authority of Austria and the National Authority for Markets and Competition in Spain, cleared the takeover in the past few weeks, according to the filing. BTG shareholders approved the purchase in March.
The fate of the deal is now in the hands of a British court, where a hearing is scheduled for August 15, 2019. If the court agrees to the acquisition, it could close August 19, with BTG shares canceled the next day.
Full Content: Investis
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Charter to Acquire Cox Communications in $35 Billion Deal
May 22, 2025 by
CPI
FTC Targets Media Watchdog Over Alleged Collusion Against Musk’s X
May 22, 2025 by
CPI
FTC Drops Antitrust Case Accusing Pepsi of Squeezing Small Retailers
May 22, 2025 by
CPI
Shein Warns of Higher Costs for French Shoppers Amid EU Fee Proposal
May 22, 2025 by
CPI
DOJ Opens Antitrust Probe of Google’s AI Partnership with Character.AI
May 22, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Industrial Policy
May 21, 2025 by
CPI
Industrial Strategy and the Role of Competition – Taking a Business Lens
May 21, 2025 by
Marcus Bokkerink
Industrial Policy, Antitrust, and Economic Growth: Some Observations
May 21, 2025 by
David S. Evans
Bolder by Design: Crafting Pro-Competitive Industrial Policies For Complex Challenges
May 21, 2025 by
Antonio Capobianco & Beatriz Marques
Competition-Friendly Industrial Policy
May 21, 2025 by
Philippe Aghion, Mathias Dewatripont & Patrick Legros